Presented at the ESC Congress 2026 and published in JACC: CardioOncology, findings from the RADICAL PC-2 trial reveal that specific modifiable cardiovascular risk factors—such as total cholesterol above 4 mmol/L and elevated blood pressure—help identify prostate cancer patients who derive more favorable intervention estimates from dedicated cardiology or internal medicine referrals.
Managing the intersection of oncology and cardiology has long presented a complex challenge for healthcare providers. When men receive a prostate cancer diagnosis or begin treatments like androgen-deprivation therapy, their underlying metabolic and vascular health often takes a backseat to primary tumor management. However, overlapping risk profiles mean that cardiovascular events frequently threaten long-term survival in this patient population. A pragmatic, international, randomized controlled trial involving nearly 2,500 participants has shed fresh light on how targeted specialist interventions can shift those outcomes.
In Plain English: The Clinical Takeaway
- Targeted Referrals Matter: Not every prostate cancer patient requires an immediate cardiologist visit, but those with pre-existing high blood pressure or high cholesterol benefit from structured cardiovascular management.
- Key Biomarkers: Total cholesterol levels exceeding 4 mmol/L and blood pressure readings at or above 130/80 mm Hg act as primary red flags indicating a need for enhanced cardiac care.
- Comprehensive Risk Reduction: The intervention model examined in the trial combined lifestyle modifications, smoking cessation, statin therapy, and blood pressure monitoring to protect patient heart health.
Unpacking the RADICAL PC-2 Trial Architecture
Led by researchers including Cristina Cano Garcia, MD, and Jehonathan Pinthus, MD, PhD, the RADICAL PC-2 (RAndomizeD Intervention for CArdiovascular and Lifestyle Risk Factors in Prostate Cancer Patients) study enrolled 2,487 participants. These patients were either newly diagnosed with prostate cancer or initiating androgen-deprivation therapy for the first time. The trial’s primary objective was to evaluate whether structured referrals to cardiologists or internists could improve clinical outcomes compared to standard care.
Patients in the interventional arm received proactive management plans that included statin therapy, systematic blood pressure monitoring, personalized lifestyle advice, and smoking cessation support. Investigators tracked a hierarchical composite primary outcome using the win ratio, which included cardiovascular death, myocardial infarction (commonly known as a heart attack), stroke, heart failure, suboptimal cholesterol levels, and systolic blood pressure control. Follow-up intervals were scheduled at 3, 6, 12, 18, and 24 months, followed by annual assessments.
According to the published data, the overall benefit of the structured intervention was largely driven by improved cholesterol control. When breaking down the data via prespecified subgroup analyses, the treatment effect differed significantly by baseline total cholesterol (≤4 mmol/L vs. >4 mmol/L, interaction P = .016) and baseline blood pressure status (systolic BP ≥130 mm Hg or diastolic BP ≥80 mm Hg vs. <130/80 mm Hg, interaction P = .003).
| Baseline Risk Factor Subgroup | Comparison Thresholds | Statistical Significance (P-Value) |
|---|---|---|
| Total Cholesterol | ≤4 mmol/L vs. >4 mmol/L | P = .016 |
| Blood Pressure | ≥130/80 mm Hg vs. <130/80 mm Hg | P = .003 |
| Diabetes Status | Diabetes present vs. absent | Not statistically significant (numerical trend observed) |
Expert Insights and Funding Transparency
The trial addresses a critical gap in cardio-oncology by attempting to establish an evidence-based roadmap for resource allocation.
Transparency regarding trial execution remains central to scientific trust. The RADICAL PC-2 trial was conducted as an independent international pragmatic evaluation. Complete disclosures for the study authors and participating investigators are available directly through JACC Journals, ensuring full accountability regarding financial or institutional relationships.
Contraindications & When to Consult a Doctor
Patients undergoing prostate cancer therapy must seek immediate medical evaluation if they experience acute cardiac symptoms. Regular coordination between an oncologist, a primary care physician, and a cardiologist remains essential for balancing cancer control with cardiovascular protection.
References
- JACC: CardioOncology. Prostate Cancer Cardiovascular Risk Factors May Help Identify Patients Who Would Benefit From Additional Cardiac Care. Published simultaneously with the ESC Congress 2026.
- European Society of Cardiology (ESC). ESC Congress 2026 Scientific Sessions and Trial Presentations.
Disclaimer: This article is intended for informational and educational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified physician or healthcare provider with any questions regarding a medical condition.
